Q-omics provides the consensus-scored SLC45A2 profile across patient tissues and cancer cell-line models. SLC45A2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC45A2 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SLC45A2 RNA expression shows 15,877 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, and KIRP as cancer lineages where SLC45A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC45A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC45A2 survival associations across molecular data types. SLC45A2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC45A2 RNA expression–survival associations across cancer types. High SLC45A2 expression shows unfavorable associations in UVM, KICH, ACC and CESC, but favorable associations in UCS and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC45A2 RNA expression.
This table summarizes SLC45A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC45A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC45A2 shows higher tumor expression in KIRP, BRCA, KIRC, LUAD, LIHC and STAD. The KIRP box plot shows higher SLC45A2 RNA expression in tumor versus normal tissue (log2 FC = +0.527, t-test p < 0.001).
This table shows molecular features associated with SLC45A2 in patient tissues and cancer cell lines. In patient samples, SLC45A2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC45A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
